Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 2/20 | 0.30 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658524 | 0.74 | NOS3 (0.43) | ASIC3TRPA1MAOAMAOBHTR2A | |
| SCHEMBL30491673 | 0.74 | NOS3 (0.43) | ASIC3TRPA1MAOAMAOBHTR2A | |
| SCHEMBL30812428 | 0.74 | TRPA1 (0.42) | ASIC3TRPA1MAOAMAOBHTR2A | |
| SCHEMBL5582897 | 0.74 | TRPA1 (0.42) | ASIC3TRPA1MAOAMAOBHTR2A | |
| SCHEMBL8024180 | 0.74 | CYP2A6 (0.48) | ASIC3TRPA1CYP3A4MAPTMAPK1 | |
| SCHEMBL20719886 | 0.74 | ASIC3 (0.40) | ASIC3TRPA1MAOAMAOBHTR2A | |
| SCHEMBL6667658 | 0.71 | ASIC3 (0.39) | ASIC3TRPA1 | |
| SCHEMBL30645172 | 0.71 | — | — | |
| SCHEMBL26667323 | 0.71 | — | — | |
| SCHEMBL843867 | 0.70 | CYP2A6 (0.37) | CYP3A4MAPK1MAOACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3909964-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-08 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| CN-115380030-B | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2025-05-16 | — | — | CN | disclosed |
| CN-119930620-A | Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20250066401-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-02-27 | — | — | US | disclosed |
| US-12152042-B2 | Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-11-26 | — | — | US | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0783498-A4 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO INC (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0783498-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5607936-A | USEFUL IN TREATMENT OF RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996010568-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1996-04-11 | — | — | WO | disclosed |
| US-4808595-A | REDUCTION OF PRESSURE DUE TO GLAUCOMA | MERCK & CO., INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4577014-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4501739-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| US-4406898-A | ANTIBIOTICS CONTAINING A THIENOPYRIDINIUM OR FUROPYRIDINIUM GROUP | ELI LILLY AND COMPANY (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0074268-A2 | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066401-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CYBA, C1S, CYC1 | ASIC3 3327/4885TRPA1 192/4885LMNA 3310/4885 |
| US-12152042-B2 | Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device | CYBA, C1S, CYC1 | ASIC3 3327/4885TRPA1 192/4885LMNA 3310/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | ASIC3 3558/4885TRPA1 2838/4885LMNA 4306/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | ASIC3 2396/4885TRPA1 4760/4885LMNA 824/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | ASIC3 4622/4885TRPA1 4617/4885LMNA 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.